Alterity Therapeutics is a biotechnology company focused on the development of innovative therapies to address neurodegenerative diseases
The company is dedicated to advancing treatments for conditions such as Alzheimer’s disease and other disorders that affect the nervous system. Through its research and clinical programs, Alterity aims to discover and commercialize novel approaches that can improve patient outcomes and enhance quality of life for those affected by these challenging conditions. The company emphasizes a science-driven strategy, leveraging cutting-edge discoveries to address unmet medical needs in the field of neurology.
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a stro
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20 per unit.
